Charting the Future of CKD Care with Multi-Drug Combinations: One Size Fits All or One Fit for Each?
- Evaluating whether all patients require the full suite of therapies or tailored combinations based on individual risk and disease drivers
- Defining optimal sequencing strategies: RAS inhibition first, or starting with the most effective therapy for each patient?
- Exploring how combination regimens of 3+ drugs can be sequenced and optimized to balance efficacy, safety, and real-world practicality
- Considering how obesity, cardiorenal pathophysiology, and kidney structural injury inform future pharmacotherapy strategies